Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
argenx
ISIN US04016X1019
|WKN A2H9WD
Marktkapitalisatie (in EUR)
43,417 m
Land
Netherlands
Sector
Healthcare
Dividendrendement
0.00%
Overzicht
Beschrijving
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands
Financiële kerngegevens
Kerncijfers
| Marktkapitalisatie, EUR | 43,417 m |
| WPA, EUR | - |
| KBV | 8.3 |
| K/W | 38.9 |
| Dividendrendement | 0.00% |
Income statement (2024)
| Omzet, EUR | 2,021 m |
| Netto-inkomen, EUR | 769 m |
| Winstmarge | 38.03% |
What ETF is argenx in?
There are 3 ETFs which contain argenx. All of these ETFs are listed in the table below. The ETF with the largest weighting of argenx is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weging | Investeringsfocus | Fondsgrootte (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 2.19% | Equity United States Health Care Biotech | 46 |
| Amundi Prime Eurozone UCITS ETF DR (D) | 0.87% | Equity Europe | 57 |
| Amundi Prime Europe UCITS ETF DR (D) | 0.47% | Equity Europe | 215 |
Nieuwste artikelen
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.
Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.